RxDoctor Payments Data

Jason Kurtz, DO

Internal Medicine · Placentia, CANPI 1104128552

Payments from drug & device makers

$1,090in general payments, 2019–2025

Across 54 payments — averaging $20.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$137
  • Biohaven Pharmaceutical Holding Company Ltd.$118
  • Takeda Pharmaceuticals U.S.A., Inc.$115
  • Amgen$95
  • Lilly USA, LLC$94
  • GSK$84
  • plus $447 from 13 others

What the payments were for

  • Food & beverage$1,090100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,090 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$64,674
Medicare patients
184
Services billed
1,694

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide112$120,373
JardianceEmpagliflozin63$64,925
EliquisApixaban37$44,836
XareltoRivaroxaban23$20,732
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$17,597
JanuviaSitagliptin Phosphate20$16,677
Aripiprazole33$8,423
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,662
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med69$3,697
Rosuvastatin Calcium231$3,521
Atorvastatin Calcium318$3,074
Levothyroxine Sodium212$2,238
Metoprolol Succinate109$2,230
Olmesartan Medoxomil125$2,186
Ipratropium Bromide76$2,175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$94$120,373112 claims
Boehringer IngelheimJardiance$137$64,92563 claims
PfizerEliquis$61$44,83637 claims
GSKTrelegy Ellipta, Anoro Ellipta$84$23,25940 claims
Johnson & JohnsonXarelto$40$20,73223 claims
MerckJanuvia$11$16,67720 claims
AbbVieSynthroid$14$1,83926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Placentia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →